Alzheimer's disease (AD) is the most common cause of dementia, accounting 60%-80% cases. Approximately 50 million people worldwide are suffering without effective treatments that can stop or reverse the disease progression.
The drug candidate EI-1071 targeting microglia-induced neuroinflammation in brain is developed by Elixiron for helping AD patients. The innovative approach has won two "Part-The-Cloud" awards (total $1.8 million US Dollars) offered by the Alzheimer's Association to support the completed and successful phase 1 clinical trial of EI-1071 (NCT04238364) in 2021 and this phase 2 in Alzheimer's disease patients approved by Food and Drug Administration Taiwan (TFDA) recently in September 28, 2023.
Elixiron is committed to developing cutting-edge immunotherapies for unmet medical needs, including AD, vitiligo, and tumors. With these approved phase 2 trials of EI-1071 in AD and of EI-001 in vitiligo, Elixiron is poised to initiate more clinical trials with its strong candidate pipelines.
